MCID: NRG005
MIFTS: 26

Neurogenic Hypertension

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Hypertension

MalaCards integrated aliases for Neurogenic Hypertension:

Name: Neurogenic Hypertension 50 69

Classifications:



Summaries for Neurogenic Hypertension

MalaCards based summary : Neurogenic Hypertension is related to neuronitis and obesity. An important gene associated with Neurogenic Hypertension is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways/superpathways is Peptide hormone metabolism. The drugs Omega 3 Fatty Acid and Minocycline have been mentioned in the context of this disorder. Affiliated tissues include brain, kidney and spinal cord.

Related Diseases for Neurogenic Hypertension

Diseases related to Neurogenic Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
id Related Disease Score Top Affiliating Genes
1 neuronitis 9.9
2 obesity 9.8
3 cervicitis 9.8
4 cerebritis 9.7
5 atherosclerosis 9.5
6 sleep apnea 9.5
7 obstructive sleep apnea 9.5
8 renal hypertension 9.5
9 cerebral atherosclerosis 9.5
10 porphyria 9.5
11 thyroiditis 9.5
12 hypoxia 9.5
13 syncope 9.5
14 neuropathy sensory spastic paraplegia 9.5 ACE2 ENPEP

Graphical network of the top 20 diseases related to Neurogenic Hypertension:



Diseases related to Neurogenic Hypertension

Symptoms & Phenotypes for Neurogenic Hypertension

Drugs & Therapeutics for Neurogenic Hypertension

Drugs for Neurogenic Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Omega 3 Fatty Acid Nutraceutical Phase 3
2
Minocycline Approved, Investigational Phase 1, Phase 2 10118-90-8 5281021
3
Fesoterodine Approved Phase 2 286930-02-7, 286930-03-8 6918558
4 Anti-Bacterial Agents Phase 1, Phase 2
5 Anti-Infective Agents Phase 1, Phase 2
6 Cholinergic Agents Phase 2
7 Cholinergic Antagonists Phase 2
8 Muscarinic Antagonists Phase 2
9 Neurotransmitter Agents Phase 2,Early Phase 1
10
Yohimbine Approved, Vet_approved Early Phase 1 146-48-5 8969
11
Melatonin Approved, Nutraceutical, Vet_approved Early Phase 1 73-31-4 896
12 Adrenergic Agents Early Phase 1
13 Adrenergic alpha-Antagonists Early Phase 1
14 Adrenergic Antagonists Early Phase 1
15 Antihypertensive Agents Early Phase 1
16 Antioxidants Early Phase 1
17 Autonomic Agents Early Phase 1
18 Central Nervous System Depressants Early Phase 1
19 Mydriatics Early Phase 1
20 Peripheral Nervous System Agents Early Phase 1
21 Protective Agents Early Phase 1
22 Yohimbe Nutraceutical Early Phase 1

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
2 Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients Recruiting NCT02133885 Phase 1, Phase 2 Minocycline Group
3 Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI) Recruiting NCT02676154 Phase 2 Fesoterodine
4 Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients Recruiting NCT02133872 Phase 1 Minocycline 100mg Group;Minocycline 200mg Group
5 Study 3: Minocycline Decreases Microglia Activation Recruiting NCT02213575 Phase 1 Minocycline
6 Adolescent Blood Pressure Variation and Ventricular Mass Completed NCT00005200
7 Brain fMRT In Takotsubo Cardiomyopathy Recruiting NCT02240056
8 Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension Not yet recruiting NCT02963181 Early Phase 1 Yohimbine;Melatonin

Search NIH Clinical Center for Neurogenic Hypertension

Genetic Tests for Neurogenic Hypertension

Anatomical Context for Neurogenic Hypertension

MalaCards organs/tissues related to Neurogenic Hypertension:

39
Brain, Kidney, Spinal Cord, Medulla Oblongata, Hypothalamus, Heart, Pons

Publications for Neurogenic Hypertension

Articles related to Neurogenic Hypertension:

(show top 50) (show all 145)
id Title Authors Year
1
Neurogenic hypertension and the secrets of respiration. ( 28438764 )
2017
2
Putative Mechanism of Salt-Dependent Neurogenic Hypertension: Cell-Autonomous Activation of Organum Vasculosum Laminae Terminalis Neurons by Hypernatremia. ( 27895191 )
2017
3
Fructose induced neurogenic hypertension mediated by overactivation of p38 MAPK to impair insulin signaling transduction caused central insulin resistance. ( 28754499 )
2017
4
Recent Advances in Neurogenic Hypertension: Dietary Salt, Obesity, and Inflammation. ( 28739972 )
2017
5
Mitochondria and Reactive Oxygen Species Contribute to Neurogenic Hypertension. ( 28615314 )
2017
6
Transcriptional networks in rodent models support a role for gut-brain communication in neurogenic hypertension: a review of the evidence. ( 28550087 )
2017
7
Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension. ( 28512108 )
2017
8
Chronic high-sodium diet intake after weaning lead to neurogenic hypertension in adult Wistar rats. ( 28720883 )
2017
9
Selective Deletion of the Brain-Specific Isoform of Renin Causes Neurogenic Hypertension. ( 27754863 )
2016
10
Contribution of Orexin to the Neurogenic Hypertension in BPH/2J Mice. ( 26975709 )
2016
11
Furosemide modifies heart hypertrophy and glycosaminoglycan myocardium content in a rat model of neurogenic hypertension. ( 27221775 )
2016
12
OS 25-02 ORIGIN OF NEUROGENIC HYPERTENSION AND THE SYMPATHO-EXCITATION IN DIET INDUCED OBESITY. ( 27754127 )
2016
13
OS 25-02 ORIGIN OF NEUROGENIC HYPERTENSION AND THE SYMPATHO-EXCITATION IN DIET INDUCED OBESITY. ( 27643054 )
2016
14
Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. ( 25489058 )
2015
15
In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope. ( 26834545 )
2015
16
I+-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17. ( 26254330 )
2015
17
Carotid body over activity induces respiratory neurone channelopathy contributing to neurogenic hypertension. ( 25900825 )
2015
18
Specific respiratory neuron types have increased excitability that drive presympathetic neurones in neurogenic hypertension. ( 24688126 )
2014
19
Presympathetic neuron dysfunction--time to reconsider increased intrinsic activity as the cause of neurogenic hypertension. ( 24987020 )
2014
20
Different impacts of I+- and I^-blockers in neurogenic hypertension produced by brainstem lesions in rat. ( 24614323 )
2014
21
The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension. ( 24002774 )
2013
22
Actions of rilmenidine on neurogenic hypertension in BPH/2J genetically hypertensive mice. ( 24275840 )
2013
23
Stabilization of hypoxia inducible factor-1I+ ameliorates acute renal neurogenic hypertension. ( 24309492 )
2013
24
Visualizing oxidative stress-induced depression of cardiac vagal baroreflex by MRI/DTI in a mouse neurogenic hypertension model. ( 23747290 )
2013
25
Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. ( 24014829 )
2013
26
Redox-sensitive oxidation and phosphorylation of PTEN contribute to enhanced activation of PI3K/Akt signaling in rostral ventrolateral medulla and neurogenic hypertension in spontaneously hypertensive rats. ( 22746319 )
2013
27
Chiari I malformation with neurogenic hypertension: case report. ( 22890471 )
2012
28
Neurogenic hypertension: revelations from genome-wide gene expression profiling. ( 22639016 )
2012
29
Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. ( 22958438 )
2012
30
Neurogenic hypertension and elevated vertebrobasilar arterial resistance: is there a causative link? ( 22562144 )
2012
31
Global identification of the genes and pathways differentially expressed in hypothalamus in early and established neurogenic hypertension. ( 21487032 )
2011
32
Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension. ( 21755262 )
2011
33
Coupling between respiratory and sympathetic activities as a novel mechanism underpinning neurogenic hypertension. ( 21445721 )
2011
34
Contributions of vascular inflammation in the brainstem for neurogenic hypertension. ( 21601658 )
2011
35
Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. ( 21536990 )
2011
36
Neurogenic hypertension. ( 20407134 )
2010
37
Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. ( 19926873 )
2010
38
Brain microglial cytokines in neurogenic hypertension. ( 20547972 )
2010
39
Inflammation and neurogenic hypertension: a new role for the circumventricular organs? ( 20651292 )
2010
40
Angiotensin-converting enzyme 2: a new target for neurogenic hypertension. ( 19923158 )
2010
41
Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. The kidney is not always the target in neurogenic hypertension. ( 21188820 )
2010
42
Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. ( 19114648 )
2009
43
Mitochondrial dysfunction and mitochondrial-produced reactive oxygen species: new targets for neurogenic hypertension? ( 19114641 )
2009
44
Do changes in the coupling between respiratory and sympathetic activities contribute to neurogenic hypertension? ( 19413588 )
2009
45
Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension. ( 19047792 )
2009
46
Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension. ( 19762685 )
2009
47
Is neurogenic hypertension related to vascular inflammation of the brainstem? ( 18585782 )
2009
48
Signalling across the blood brain barrier by angiotensin II: novel implications for neurogenic hypertension. ( 18443753 )
2008
49
Specific inflammatory condition in nucleus tractus solitarii of the SHR: novel insight for neurogenic hypertension? ( 18722165 )
2008
50
Aminopeptidase A: could it be a novel target for neurogenic hypertension? ( 18362227 )
2008

Variations for Neurogenic Hypertension

Expression for Neurogenic Hypertension

Search GEO for disease gene expression data for Neurogenic Hypertension.

Pathways for Neurogenic Hypertension

Pathways related to Neurogenic Hypertension according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
10.88 ACE2 ENPEP

GO Terms for Neurogenic Hypertension

Biological processes related to Neurogenic Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.26 ACE2 ENPEP
2 angiotensin maturation GO:0002003 9.16 ACE2 ENPEP
3 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.96 ACE2 ENPEP
4 angiotensin catabolic process in blood GO:0002005 8.62 ACE2 ENPEP

Molecular functions related to Neurogenic Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.16 ACE2 ENPEP
2 peptidase activity GO:0008233 8.96 ACE2 ENPEP
3 metallopeptidase activity GO:0008237 8.62 ACE2 ENPEP

Sources for Neurogenic Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....